Innovating Works

PAMGENE INT BV

Desconocido
ROUTINE: canceR agnOstic immUnoTherapy predIctioN blood-tEst PAMGENE INTERNATIONAL BV tramitó un HORIZON EUROPE: HORIZON-EIC-2023-ACCELERATOR-01 Cancer is the second leading cause of death worldwide, accounting for 10M deaths in 2020. Although 7 Immune Checkpoint Inhibitors (ICI) are...
2023-11-20 - 2025-07-31 | Financiado
EDCMET: Metabolic effects of Endocrine Disrupting Chemicals novel testing METhods and adverse outcome pathw... PAMGENE INTERNATIONAL BV participó en un H2020: H2020-SC1-BHC-2018-2020 Endocrine disruptors (EDs) are defined as exogenous chemicals that alter functions of the endocrine system, thereby causing adverse health e...
2018-11-21 - 2024-06-30 | Financiado
transMed: Educating the next generation of scientists in translational medicine Focus on eye diseases PAMGENE INTERNATIONAL BV participó en un H2020: H2020-MSCA-ITN-2017 Medicine today experiences a gap between basic research and successful clinical translation that delays establishment of urgently needed the...
2017-08-29 - 2021-11-30 | Financiado
UM Cure 2020: New therapies for uveal melanoma PAMGENE INTERNATIONAL BV participó en un H2020: H2020-PHC-2014-2015 Uveal melanoma (UM) is a rare intraocular tumour with an incidence of 5 cases per million individuals per year. Up to 50% of UM patients dev...
2015-12-02 - 2021-06-30 | Financiado
EUROTARGET: European collaborative project on Targeted therapy in renal cell cancer genetic and tumor related b... PAMGENE INTERNATIONAL BV participó en un FP7: Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized ren...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.